According to IQVIA (IMS Health), Reyataz and its generic equivalents had US sales of approximately $324mn for the 12-month period ending April 2018.
Cipla has received final approval for its abbreviated new drug application (ANDA) for Atazanavir Caps 100mg, 150mg, 200mg, and 300mg from the United States Food and Drug Administration (USFDA).
According to IQVIA (IMS Health), Reyataz and its generic equivalents had US sales of approximately $324mn for the 12-month period ending April 2018.
Cipla’s Atazanavir Caps 100mg, 150mg, 200mg, and 300mg are an AB-rated generic therapeutic equivalent version of Bristol-Myers Squibb Pharma Company’s, Reyataz. It is a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients aged 6 years and older and weighing at least 15 kg.
